New Triple-Target antibody enters human testing for tough cancers
NCT ID NCT07055594
Summary
This early-stage trial is testing a new three-target antibody called SOA101 in people with advanced solid tumors that have stopped responding to standard treatments. The study will first determine safe dosage levels, then look for initial signs that the treatment might help control cancers like lung, ovarian, breast, head/neck, and colorectal. Participants must have tumors that show a specific marker (PD-L1) and be in generally good health aside from their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
China Medical University Hospital
RECRUITINGTaichung, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.